Radius Health announced positive topline results from the ATOM study evaluating Tymlos (abaloparatide) 80mcg subcutaneous (SC) for use in males with osteoporosis.
Radius Health has presented response rates for bone mineral density (BMD) in osteoporosis patients treated with Tymlos (abaloparatide) followed by...
Radius Health, Inc. has announced that the FDA has approved Tymlos (abaloparatide) injection for the treatment of postmenopausal women with...
Radius Health announced that the FDA has approved Tymlos (abaloparatide), a parathyroid hormone related peptide [PTHrP(1-34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.
Radius Health, Inc. announced phase III topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (Tymlos) in postmenopausal women with osteoporosis.